This page shows the latest Fasenra news and features for those working in and with pharma, biotech and healthcare.
AstraZeneca has delivered another period of strong growth thanks to robust performances across all regions and disease areas, particularly oncology, new CVRM and Fasenra in respiratory.
medicines such as Imfinzi and monoclonal antibody Fasenra (benralizumab).
AZ’s own interleukin-5 inhibitor (IL-5) Fasenra (benralizumab) is approved as an add-on maintenance treatment for eosinophilic asthma, while another IL-5 inhibitor from GlaxoSmithKline’s IL-5
as AstraZeneca’s asthma injection Fasenra(benralizumab).
GSK is trying to keep the first-to-market IL-5 inhibitor ahead of other drugs in the class, particularly AstraZeneca’s Fasenra (benralizumab) which is gaining ground fast with
AZ’s respiratory franchise also grew 18% to $1.3bn – although the company saw a 4% decline in sales of Symbicort, this was offset by the growth of Pulmicort and Fasenra,
More from news
Approximately 7 fully matching, plus 19 partially matching documents found.
But GSK is not alone in the IL-5 inhibitor arena. AstraZeneca’s Fasenra is making waves with its eight-week dosing schedule and $296m in first-half sales – a 244%
AstraZeneca launched five significant new medicines in 2017: immunotherapy Iminzi, Calquence for mantle cell lymphoma, Qtern in type 2 diabetes, Bevespi Aerosphere in COPD and Fasenra for severe asthma.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Since joining MedImmune in 2006, Bahija has overseen the development of several new medicines, including Imfinzi, Fasenra, Lumoxiti, Siliq and FluMist Quadrivalent.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Operating in 50+ countries, we’re a leading research, educational, and professional publisher dedicated to advancing scientific discovery. Whether you’re looking...